Thirty-three patients were operated on for cystic tumors of the pancreas at the Vishnevsky Institute of Surgery in 1980-90. Cystadenoma of the pancreas was found in 16 (48.5%) of them and cystadenocarcinoma in 15 (45.5%). Fifteen (45.5%) patients had been previously operated on in different institutions presumably for a "cyst" of the pancreas, 6 of them repeatedly; the tumor recurred rapidly in all of them. In the Institute 30 patients underwent radical operations: 30 distal resection of the pancreas and 5 pancreatoduodenal resection. Diagnostic and palliative manipulations were performed on 3 patients. Postoperative lethality was 9.1% (3 patients). Postoperative follow-up periods lasted from 12 months to 9 years. Dissemination of the tumor occurred in 2 patients two years after the operation. The remaining 25 patients are alive and capable of working.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Drug Development.
Alzheimers Dement
December 2024
Mashhad University of Medical Sciences, Mashhad, Razavi Khorasan, Iran (Islamic Republic of).
Background: Microbiota of the distal part of the intestine produces Urolithin A (Uro A) as a derivative of ellagitannins hydrolysis. Recently, the mitophagy, anti-inflammatory, and antioxidant properties of Uro A have focused more attention on its probable beneficial effects on neurodegenerative states. The purpose of this research was to study the impact of Uro A on the histopathology of the cerebellum in a rat model of streptozotocin-induced Alzheimer's disease.
View Article and Find Full Text PDFBackground: Alzheimer's disease (AD) presents unique challenges in clinical trials involving small molecules. Multifaceted issues plague such trials, emphasizing susceptibility to fraud from clinical sites and "professional patients". The relative ease of simulating Alzheimer's diagnosis, coupled with inadequate oversight by Contract Research Organizations (CROs), creates fertile ground for deceptive practices.
View Article and Find Full Text PDFBackground: A 73-year-old female with a 3 year history of Alzheimer's disease was treated within the protocol of The Alzheimer's Autism and Cognitive Impairment Stem Cell Treatment Study (ACIST), an IRB approved clinical study registered with clinicaltrials.gov NCT03724136.
Method: The procedure consists of bone marrow aspiration, cell separation using an FDA cleared class 2 device, and intravenous and intranasal administration of the stem cell fraction.
Evaluation of the Patient Global Impression of Symptom Severity (PGISS) Score as a Subjective and Objective Measure of Disease Activity in Chronic Rhinosinusitis.
Am J Rhinol Allergy
January 2025
Department of Otolaryngology - Head and Neck Surgery, Eastern Virginia Medical School, Norfolk, VA, USA.
Background: The Sino-nasal Outcome Test (SNOT-22) is a 22-question survey that is utilized to evaluate health-related quality of life of patients with chronic rhinosinusitis (CRS). The Patient Global Impression Symptom Severity (PGISS) is a similar yet versatile instrument that combines features of both a Likert scale and a visual analog to assess symptom severity in CRS patients. While previous studies have evaluated the validity of SNOT-22 as an instrument to measure CRS patients' symptom severity, no studies have evaluated PGISS scale's ability to evaluate and guide treatment plans for CRS patients.
View Article and Find Full Text PDFOutcomes of Immunotherapy Treatment in Sinonasal Mucosal Melanoma.
Am J Rhinol Allergy
January 2025
Department of Otorhinolaryngology-Head and Neck Surgery, University of Pennsylvania, Perelman School of Medicine, Philadelphia, Pennsylvania.
Background: Sinonasal mucosal melanoma has poor survival despite multimodality treatment. While the impact of immunotherapy (IT) on metastatic cutaneous melanoma is well-defined, there are relatively little data on sinonasal mucosal melanoma.
Objective: We sought to define immunotherapy outcomes in patients with sinonasal mucosal melanoma.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!